Integration of Enzymatic Transformation and Self‐Assembly for Future Cancer Therapy

Bing Xu,Xuewen Du,Jie Zhou,Junfeng Shi,Jie Li

DOI: https://doi.org/10.1096/fasebj.29.1_supplement.897.9

2015-01-01

Abstract:Molecular-targeted therapeutics, which are mostly based on ligand-receptor interaction or enzyme inhibition, have been a key strategy for developing cancer drugs. However, the great complexity of cancers limits the current cancer therapy that aims to only one or two molecular targets. Thus, we integrate enzyme transformation (ET) and self-assembly (SA) for generating the fibrils of small molecules as potential anticancer therapeutics (Fig 1). Inspired by collagen fibril assembly in which enzymes cleave propeptides to transform procollagens to collagen molecules that self-assemble into collagen fibrils, we synthesize a molecule with two parts; an amphiphilic, self-assembling block joined to a hydrophilic block which renders the conjugate water soluble. We design the hydrophilic group prone to be cleaved by an enzyme associated with cancer. The enzyme cleaves the two blocks, triggering the self-assembly of the amphiphiles, which acts as an anticancer agent when non-covalently assembled as fibrils, but has no cytotoxicity in the soluble, monomer form. Our studies show that ET&SA generate fibrils of small molecules to selectively inhibit drug-resistant cancer cells in vitro and in vivo, implying that the mechanisms of action of the molecular fibrils to cancer cells significantly depart from the ligand-receptor dogma of current anticancer drugs. Our results suggest that enzymatic transformation is able to target “undruggable” or “untargetable” features of cancer cells; self-assembly allows simultaneously interaction with multiple targets for inhibiting cancer cells. Therefore, the integration of enzymatic transformation (ET) and self-assembly (SA) of small molecules promises a paradigm-shift approach for future cancer therapy.